About Us
Services
Publications
Latest News
Career
Contact Us
Congratulations to IMPACT THERAP-B (Stock Code: 7630.hk) on the Successful IPO on the Main Board of the HKEX!
Congratulatory
2026/05/13

Congratulations to

IMPACT THERAP-B (Stock Code: 7630.hk)

on the Successful IPO on the Main Board of the HKEX!

 

COMPANY PROFILE

Founded in 2009, Impact Therapeutics (IMPACT THERAP-B) is a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients.

(Source:https://www.impacttherapeutics.com/) 

 

CR SWCS Team is honoured to serve as

IMPACT THERAP-B's Joint Company Secretary,

committed to ensuring governance,

compliance, and sustained growth.